Galapagos NV $GLPG Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA reduced its holdings in Galapagos NV (NASDAQ:GLPG) by 64.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 50,500 shares of the biotechnology company’s stock after selling 92,810 shares during the period. Primecap Management Co. CA’s holdings in Galapagos were worth $1,749,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GLPG. State of Wyoming purchased a new stake in Galapagos during the 2nd quarter valued at about $28,000. GAMMA Investing LLC boosted its holdings in shares of Galapagos by 79.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,473 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 652 shares during the last quarter. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Galapagos in the third quarter valued at approximately $212,000. Ascent Group LLC acquired a new stake in shares of Galapagos in the third quarter valued at approximately $219,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Galapagos in the second quarter valued at approximately $220,000. 32.46% of the stock is currently owned by institutional investors and hedge funds.

Galapagos Stock Up 0.5%

Shares of Galapagos stock opened at $33.66 on Friday. Galapagos NV has a 52 week low of $22.59 and a 52 week high of $37.78. The business’s fifty day simple moving average is $33.61 and its 200-day simple moving average is $32.77.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Sanford C. Bernstein began coverage on Galapagos in a research note on Wednesday, November 26th. They set a “hold” rating on the stock. Royal Bank Of Canada lifted their price target on Galapagos from $32.00 to $33.00 and gave the stock a “sector perform” rating in a report on Tuesday. UBS Group reissued a “market perform” rating on shares of Galapagos in a report on Tuesday. Weiss Ratings upgraded shares of Galapagos from a “sell (d)” rating to a “hold (c)” rating in a research report on Thursday. Finally, Wall Street Zen raised shares of Galapagos from a “sell” rating to a “hold” rating in a research note on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Galapagos presently has a consensus rating of “Hold” and an average price target of $36.50.

About Galapagos

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.